These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29107144)

  • 1. Osteon Myospalacem Baileyi attenuates osteoclast differentiation through RANKL induced NFAT pathways.
    Cui Y; Zhao X; Mei L; Pei J; Wang S; Shao Y; Tao Y; Zhang X; Jiang L
    J Ethnopharmacol; 2018 Mar; 213():65-71. PubMed ID: 29107144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression.
    Cheon YH; Baek JM; Park SH; Ahn SJ; Lee MS; Oh J; Kim JY
    BMC Complement Altern Med; 2015 Aug; 15():280. PubMed ID: 26271279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
    Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY
    Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel two-dimensional preparative chromatography method designed for the separation of traditional animal Tibetan medicine Osteon Myospalacem Baileyi.
    Jiang L; Tao Y; Wang D; Tang C; Shao Y; Wang Q; Zhao X; Zhang Y; Mei L
    J Sep Sci; 2014 Nov; 37(21):3060-6. PubMed ID: 25142979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Berberine Sulfate Attenuates Osteoclast Differentiation through RANKL Induced NF-κB and NFAT Pathways.
    Zhou L; Song F; Liu Q; Yang M; Zhao J; Tan R; Xu J; Zhang G; Quinn JM; Tickner J; Xu J
    Int J Mol Sci; 2015 Nov; 16(11):27087-96. PubMed ID: 26580592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
    Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
    Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Aronia melanocarpa 'Viking' Extracts in Attenuating RANKL-Induced Osteoclastic Differentiation by Inhibiting ROS Generation and c-FOS/NFATc1 Signaling.
    Ghosh M; Kim IS; Lee YM; Hong SM; Lee TH; Lim JH; Debnath T; Lim BO
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29518052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
    Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
    FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity.
    Song F; Zhou L; Zhao J; Liu Q; Yang M; Tan R; Xu J; Zhang G; Quinn JM; Tickner J; Huang Y; Xu J
    J Cell Physiol; 2016 Sep; 231(9):1983-93. PubMed ID: 26754483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways.
    Abdallah BM; Ali EM; Elsawy H; Badr GM; Abdel-Moneim AM; Alzahrani AM
    Biomed Res Int; 2019; 2019():9395146. PubMed ID: 31976330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
    Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
    J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 9-Hydroxy-6,7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1.
    Kim JY; Kim JY; Cheon YH; Kwak SC; Baek JM; Kim YC; Yoon KH; Oh J; Lee MS
    Int Immunopharmacol; 2014 May; 20(1):213-20. PubMed ID: 24630975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.